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ABSTRACT: γ-secretase is a membrane protease complex
that catalyzes the cleavage of the amyloid precursor protein to
produce the infamous Aβ peptides involved in Alzheimer’s
disease (AD). Major eﬀorts aim to modulate this cleavage to
reduce the formation of longer, more toxic Aβ peptides, yet the
molecular basis of this modulation remains unknown. We
studied the quantitative structure−activity relations using a
carefully curated data set of 60 experimental EC50 values (the
GSL60 data set). To ensure adequate optimization, we used 10
diﬀerent methods to build the models, Y-randomization, 10-
fold repeated cross-validation, and explicit external validation
on a secondary data set. Neural network optimization best
reproduced experimental log EC50. We ﬁnd that only four
descriptors, the number of hydrogen-bond acceptor sites, the
topology of the drug, the dehydration energy, and the binding energy to γ-secretase, deﬁne most of the potency of γ-secretase
modulators. We explain this as a compromise between the binding free energy to the protein and required hydrogen bond
networks in the actual modulatory sites. Our model suggests that many molecules can modulate cleavage simply by contributing
their binding energy to stabilize the compact ternary complex with C99. This result is in line with a mechanism, referred to here
as FIST (Fit, Stay, Trim), where stronger binding to the semiopen state leads to longer retention time and maximal C99
trimming to produce shorter innocent Aβ peptides, whereas AD-causing PSEN1 mutations favor the open state by reducing
hydrophobic packing, retention time, and trimming and modulators strengthen interactions in the ternary complex to increase
the C99 retention time and trimming, ultimately producing more short, nonpathogenic Aβ peptides. Our results may aid the
development of new γ-secretase modulators with optimal hydrogen bonds, shape, and hydrophobicity but more importantly
provide a structural−chemical model of the modulation of Aβ production.
■ INTRODUCTION
Alzheimer’s disease (AD) is a devastating chronic neuro-
degenerative disease, characterized by progressive loss of
memory, cognitive impairment, and personality change; it
constitutes up to 60% of all dementia cases and thus aﬀects
more than 30 million people worldwide.1,2 Despite many years
of research and attempts to develop therapies, there is still no
cure for AD or even an eﬀective therapy to signiﬁcantly stall
AD symptoms for more than a few months.3 This is largely
because the disease is biochemically extremely complex and
accordingly mainly occurs sporadically, with many risk
modiﬁers. Thus, there is an urgent need to develop new
molecular insight and strategies for prevention and treatment.
Accumulation of senile plaques composed of aggregates of
longer forms of β-amyloid peptides (Aβ42 or Aβ43) is a main
pathological hallmark of the disease,4 and oligomers seeded
early in this aggregation process are widely considered to be
pathogenic.5,6 A molecular understanding of the factors that
regulate Aβ production is thus crucial for combatting the
disease.7 Aβ peptides derive from the sequential cleavage of the
amyloid precursor protein by ﬁrst β-secretase,8−10 generating
C-terminal fragments with 99 amino acids (C99), which are
then cleaved by γ-secretase11,12 to produce Aβ peptides of
diﬀerent lengths (37−43). The formation occurs directly in the
membrane, and the lipid−protein interactions thus aﬀect the
length, chemical properties, and aggregation tendency of the
Aβ peptides.13−16 The longer Aβ42 and Aβ43 isoforms are
highly aggregation-prone and more toxic in cell cultures.17
Their involvement in the disease18 is supported by mutations
in presenilin7 isoforms PSEN1 and PSEN2 that cause early-
onset AD; in almost all cases, these mutations increase the
ratio of Aβ42/Aβ40 peptide isoforms produced by γ-
secretase,19,20 and this ratio is larger for more severe early-
onset mutations.21 γ-secretase contains four subunits:
Presenilin is the catalytic subunit, whereas nicastrin, anterior
pharynx-defective 1, and presenilin enhancer 222−24 play
important roles in guiding the C99 substrate entry and
exit.11,12
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Direct nonselective inhibition of the protein complex causes
side eﬀects which are widely thought to be due to the
unwanted inhibition because more than 90 substrates are
cleaved by the enzyme complex, including the important notch
receptor.25−27 Alternatively, there is increasing evidence that
the reduction in shorter Aβ40 may cause a loss of function of
this peptide that could also cause side eﬀects.28 Consequently,
focus has moved toward γ-secretase modulators.29 These
compounds preferentially lower Aβ42 production without
interfering with the cleavage of the other substrates by γ-
secretase as they supposedly interact with γ-secretase via
multiple allosteric binding sites.7,30 They tend to favor the
production of shorter Aβ peptides, most commonly Aβ38,
31,32
and Notch signaling is supposedly not aﬀected by them.33 The
γ-secretase modulators are quite structurally diverse but can be
crudely divided into at least three groups.34−37 The ﬁrst
generation consists of derivatives of nonsteroidal anti-
inﬂammatory drugs (NSAID). These modulators reduce Aβ42
and increase production of shorter peptides such as Aβ38
through allosteric modiﬁcation of the interaction between the
presenilin catalytic site and C99. Second-generation modu-
lators are structurally diverse and commonly exhibit stronger
potency and bioavailability. The third group consists of natural
products whose eﬃciency and safety may vary greatly.2
To date, the molecular mechanism that enables γ-secretase
modulators to change the Aβ production remains unclear.
Given their importance, it seems necessary to understand how
these molecules work, which chemical properties that make
them function, and how they can be rationally optimized for
increased potency. Quantitative structure−activity relation-
ships (QSARs) are state-of-the-art tools for understanding
these molecular mechanisms and predicting potency. Very few
QSAR studies38,39 have been directed toward γ-secretase
modulators, presumably because the molecular mechanism of
modulation is more complex and depends on multiple
modulatory sites on the protein surface, whereas classical
Figure 1. (A) Structure of the semiopen state of γ-secretase with the four subunits nicastrin (green), PS1 (cyan and magenta), APH-1 (yellow), and
PEN-2 (pink) used in this work. (B) Score plot showing the ﬁrst three principal components (PCs). The green triangles represent modulators with
EC50 < 100 nM; blue squares represent modulators with 100 nM < EC50 < 500 nM; red dots represent modulators with 500 nM < EC50 < 10 000
nM; and purple diamonds represent modulators with EC50 > 10 000 nM. The bigger size indicates that more than one modulator has the same PC
coordinates.
Figure 2. (A) Representative compounds from the GSL60 data set (for a complete list, see Supporting Information). (B) ROC analysis for using
the descriptors to distinguish modulators with an EC50 cutoﬀ of 100 nM. The ﬁgure shows the ROC curves of the top 10 descriptors (AUC = area
under the curve).
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inhibitor models can rely on binding to only the active site of
the enzyme.
In this work, we compiled a diverse, curated data set of γ-
secretase ligands and used a wide suite of regression- and
machine-learning methods to build the ﬁrst accurate QSAR
models of γ-secretase modulation, based on quantum
mechanical properties of the molecules, binding energies, and
their physical components. The models were subject to
randomized 10-fold internal as well as explicit external
validation. We applied the most complete previously
established full-atom γ-secretase structure which obeys all
available experimental structural constraints and was equili-
brated by 500 ns of molecular dynamics (MD) simulations.40
The active semi-open state of this protein is shown in Figure
1A. This structure importantly includes all helix side chains,
loops, the maturation cleavage into N- and C-terminal
fragments required for activity, a membrane, and other features
missing in the cryo-electron microscopy structures.41 Using
this modeling approach, we ﬁnd that strong versus weak
modulatory eﬀects can be described by only four descriptors,
providing a simple molecular recipe for developing new
modulators for the potential treatment of AD.
Figure 3. Linear relationship between log EC50 values and the numerical values of the calculated chemical properties of the modulators.
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■ RESULTS AND DISCUSSION
Descriptor Classiﬁcation and Principal Component
Analysis. As the ﬁrst part of our analysis, we removed the
noninformative and zero-variation descriptors, leaving 38
meaningful descriptors as shown in the Supporting Informa-
tion (XLSX ﬁle). Highly correlated descriptors (R2 > 0.9) were
not included simultaneously. In general, only clearly
informative and meaningful, nonredundant descriptors should
be used to build a prediction model. For the descriptor
selection, we ﬁrst performed principal component analysis with
the data scaled to zero mean and unit variance; the resulting
score plot is shown in Figure 1B. The ﬁrst three PCs explain
61.8% of the total variation, with the PC1, PC2, and PC3
accounting for 28.5, 18.8, and 14.5%, respectively. The points
are colored according to the EC50 values. The score plots
clearly indicate a good separation of the modulators with high
EC50 values (purple diamonds). However, Figure 1B exhibits
less eﬀective separation for the ﬁrst three PCs for other
modulators, indicating the challenge of modeling very potent
modulators. Examples of weak and strong modulators are
shown in Figure 2A.
To further analyze this, cluster analysis based on Euclidian
distance was performed based on the used descriptors. The
dendrogram and associated heat map are shown in Figure S1
(Supporting Information). In general, two main clusters were
found and the modulators with high EC50 values were grouped
within the same cluster, in agreement with the principal
component analysis (PCA) results. The individual loading
plots are shown in the Supporting Information (Figures S2−
S4). PC1 is more positively correlated with the binding free
energy (ΔGbind) and to log EC50 and negatively correlated with
the sum of the degrees (SD), which describes the complexity of
the ligand. PC2 is mainly characterized by the Cosmo solvation
energy (dielectric energy in water, Esol) and the number of
rotatable bonds. On the basis of the PCA analysis, the most
promising 10 descriptors were selected for further QSAR
modeling. These selected descriptors cannot separate the
modulators with relatively low EC50 values but may be capable
of predicting whether a prospective modulator will be potent
or not.
Descriptor Selection Using Diﬀerent Methods. The
PCA led us to attempt to reduce the complexity of the QSAR
models. To this end, receiver operating characteristic (ROC)
curve analysis (Figure 2B) was applied to the data set. For the
binary classiﬁcation using the ROC curve analysis, the EC50
value of 100 nM was used as a cutoﬀ and the descriptors were
used as predictors. Figure 2B lists the top 10 descriptors
according to the obtained AUC values. If the descriptor can
perfectly separate the modulators, the area under the ROC
curve equals 1. As can be seen from Figure 2B, the total
connectivity was the best descriptor (AUC of 0.72) for
separating the modulators using a cutoﬀ value of 100 nM,
followed by polar surface area (AUC of 0.71) and the number
of hydrogen-bond acceptor sites of the drug NH (AUC of
0.71). The top 10 descriptors from this analysis were selected
for further modeling.
Another approach, random forest, may improve variable
selection. This backward selection method quantiﬁes the
relevance of the descriptors based on importance as shown in
Figure S5 (Supporting Information). The total connectivity
again ranked highly for predicting the log EC50 values. We
found good consensus between the ROC analysis and the
random forest method, as 6 of the top 10 descriptors selected
by ROC analysis also entered the top 10 proposed from
random forest optimization; the four additional descriptors
were also considered for building QSAR models.
The linear relationship between log EC50 and the studied
descriptors was determined, and the results are shown in
Figure 3. We were surprised to ﬁnd that some descriptors
(such as SD) showed some linear relationships with R
2 up to
0.39 (p < 0.001). On the basis of the linear regression and the
linear relationship in Figure 3, 10 additional descriptors were
considered. With these diverse selected descriptors as the
starting point, 4 data sets were obtained with 10 descriptors
each. Each time, four descriptors were used for QSAR
modeling. In total, 840 test data sets were produced in this
way and subsequently used to construct predictive QSAR
models. Highly correlated descriptors (R2 > 0.9) were reduced
to only one to avoid overﬁtting.
Neural Network-Optimized QSAR Model of EC50. The
summary of the best regression method performance for all of
the obtained models based on the evaluation metrics is shown
in Table S3 (Supporting Information). As seen from Table S3,
the performance of the obtained models vary a lot, and most
R2 values were quite low as expected, indicating the challenge
of describing the experimentally observed activity of these
Table 1. Evaluation Metrics (R2, Adjusted R2, and Root-Mean-Squared Error for the Training Data Set, Test Data Set, and the
Whole Data Set) of the 10 Methods Used for Building the QSAR Modelsa,b
method adj.R2 (train) RMSE (train) R2 (train) adj.R2 (test) RMSE (test) R2 (test) adj.R2 (both) RMSE (both) R2 (both) # descriptors
nnet 0.56 0.66 0.56 0.47 0.70 0.56 0.59 0.65 0.61 4
glmnet 0.51 0.71 0.54 0.41 0.74 0.51 0.54 0.69 0.57 4
lm 0.51 0.71 0.54 0.41 0.73 0.51 0.54 0.68 0.57 4
lassoRMSE 0.52 0.71 0.54 0.41 0.75 0.50 0.54 0.69 0.57 3.7
glmStepAIC 0.50 0.75 0.53 0.37 0.76 0.48 0.52 0.69 0.55 4
pls 0.45 0.70 0.56 0.37 0.77 0.48 0.49 0.72 0.52 4
rfRFE 0.87 0.73 0.51 0.39 0.78 0.48 0.70 0.59 0.71 3.4
rf 0.89 0.76 0.49 0.35 0.78 0.46 0.69 0.57 0.72 4
svmRFE 0.55 0.77 0.54 0.27 0.88 0.38 0.48 0.78 0.51 3.6
svmRadial 0.68 0.77 0.52 0.20 0.87 0.34 0.53 0.68 0.56 4
aThe four descriptors are the number of hydrogen-bond acceptor sites (NH), the sum of degrees (SD), the solvation energy in water (Esol), and the
binding free energy to γ-secretase (ΔGbind). bnnet = Neural network; glmnet = elastic net regression; lm = multiple linear regression; lassoRMSE =
lasso regression; glmStepAIC = generalized linear model with stepwise feature selection; pls = partial least-squares regression; rfRFE = random
forest with recursive feature elimination; rf = random forest; svmRFE = support vector machine with recursive feature elimination; and svmRadial =
support vector machine using radial functions.
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diverse compounds. On the basis of R2 and root mean square
error (RMSE) values, four descriptors, NH, SD, the solvation
energy of the drug in water (Esol), and ΔGbind computed by
AutoDock Vina showed the best combined ability to describe
the log EC50 values. The evaluation metrics of all applied
methods for these four descriptors are summarized in Table 1.
Neural network optimization was most capable of ﬁtting the
descriptors to predict log EC50, with R
2 = 0.61 and adjusted R2
= 0.59, respectively, followed by elastic net regression and
multiple linear regression. The applied neural network model is
shown in Figure S6 of the Supporting Information. The model
has four input-layer neurons equal to the used descriptors and
ﬁve hidden-layer neurons and a single output-layer neuron.
The networks were trained using the Broyden−Fletcher−
Goldfarb Shanno algorithm, and decay values of 0, 0.001, and
0.1 were used to avoid overﬁtting.42
To interpret the neural network models, the coeﬃcients of
each layer can be obtained as shown in Table S4 of the
Supporting Information. We found that ΔGbind of the drug to
the protein has substantial contributions to the third and ﬁfth
hidden-layer neurons with coeﬃcients of 1.11 and 1.12,
respectively. As hidden-layer neurons had high contribution to
the out-layer neuron, we conclude that ΔGbind, as measured by
AutoDock Vina calculation on the semiopen structure,
contributes substantially to the observed log EC50 values.
The ﬁnal performance of the neural network model is shown in
Figure 4.
Explicit external validation of our models was carried out
using 10 additional randomly selected modulators not part of
our GSL60 data set but with a similar chemical structure and
within the same range of log EC50. The results of this external
validation are shown in Figure S7. Although R2 values were
reduced to 0.33−0.34, considering the complexity of the
modulatory eﬀect and the high diversity of the data set, this
performance is encouraging. As shown in Table 1, the
multilinear regression method also produced good perform-
ance as indicated by R2 and RMSE values. The ﬁnding that
four-descriptor models can describe and pseudopredict high
versus low log EC50 values is of signiﬁcance to our future
eﬀorts in understanding γ-secretase and its modulation for
therapeutic purposes.
Chemical Interpretation of the Obtained Modulation
Model. To understand the molecular basis of modulation, the
multilinear regression model was also interpreted in detail. The
performance of the model is shown in Figure 4 (right panel)
with the external validation shown in Figure S7. Because
normalization was used during modeling, to obtain the
coeﬃcients corresponding to the original data set, the scaled
coeﬃcients were multiplied by a scaling factor giving the model
of eq 1
= − − −
+ Δ
N S E
G
log EC 6.38 0.14 0.02 0.43
0.24
50 H D sol
bind (1)
The solvation energy in water had the strongest contribution
to the trend prediction (its removal reduces R2 by 0.1),
whereas the other three terms are of similar importance. In
terms of their contribution to the modeled log EC50 value,
their relative importance is roughly 0.9, 1.4, 0.6, and 2.2, as
measured by their eﬀect on the mean signed error of predicted
log EC50 when removing the term. The identiﬁed descriptors
were not highly correlated, indicating that they are informative
in diﬀerent ways.
Because both energy terms are computed as negative
numbers (with more negative meaning stronger binding
energy to water or protein, respectively), the last two terms
Figure 4. Linear relationship between the measured and predicted log EC50 values based on the neural network model (left panel) and multiple
linear regression model (right panel).
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essentially represent the dehydration penalty and the protein−
ligand binding energy contributions to the potency of the
modulator, that is, the two terms describe the net strength of
the ligand−protein interaction. The signs are thus directly
physically meaningful and the two terms compete to aﬀect the
EC50 value.
Stronger association of the modulator with the protein due
to these two terms contributes signiﬁcantly to explaining
experimental EC50 values. In contrast, any molecular
mechanism that explains how these compounds selectively
lower Aβ42 peptide production is, at this point, elusive.
However, recent work suggests that two distinct modulators
change the conformation state of γ-secretase explicitly.43 Our
results indicate that the structural requirements for γ-secretase
modulation diﬀer widely for the 60 studied compounds, which
is probably due to the presence of multiple distinct modulatory
sites.44 This complication makes the importance of model (1)
more evident because it reproduces log EC50 without any use
of information of these variable modulatory binding sites but
only general nonspeciﬁc binding information as well as
information relating to the interaction types of the ligand
with the protein surface.
To understand the modulatory eﬀect in more detail, we
divided the modulators into six groups based on their EC50
values, and the four chemical properties obtained from QSAR
modeling were displayed for each group (Figure 5). There is
no simple correlation between the binding energy and the
observed activity, and the binding energy varies substantially
among the groups. The residues in the binding sites also
contribute to the interactions and volume of the binding
pocket.45 In addition to the two energy terms that compete to
produce the overall drug aﬃnity, the number of hydrogen
bond acceptor sites (NH) in the compound contributes
consistently to lowering log EC50. The ROC analysis showed
the importance of this descriptor for distinguishing modulators
with low EC50 values (100 nM). Despite the substantial
variation among the groups of compounds, it is notable that
modulators with lower EC50 values tend to have more
hydrogen-bond acceptor sites.
Larger molecules, all else being equal, are more capable of
aﬀecting the conformational state of a protein and will also,
again all else being equal, bind more strongly. Accordingly, the
number of hydrogen bond acceptors is a prominent feature in
many pharmacophore-based QSAR models.46 Combining this
with the insight from the dehydration penalty (the dielectric
energy in eq 1), we conclude that potent γ-secretase
modulators should be relatively hydrophobic while still
possessing lone-pair electrons on heteroatoms to modulate γ-
secretase eﬃciently. The importance of the hydrogen-bond
acceptors has been addressed in previous attempts to develop
new γ-secretase modulators.47 Previous work has shown that
some modulators interact with γ-secretase through hydrogen
bonds and π−π interactions.48
Solvation eﬀects contribute substantially to the variations in
binding energy between relatively similar ligands.49 We were
intrigued that the dehydration penalty, as estimated by the
Cosmo solvation energy of the modulators in water,
contributes substantially to the measured EC50. Despite
being a QM/density functional theory (DFT) calculation, it
can be performed routinely for many compounds using the
Figure 5. Distribution of values of log EC50 and of the four best descriptors of log EC50 divided into ﬁve groups of modulators: group A has EC50 <
50 nM; group B has 50 nM < EC50 < 100 nM; group C has 100 nM < EC50 < 200 nM; group D has 200 nM < EC50 < 300 nM; group E has 300
nM < EC50 < 500 nM; and group F has EC50 > 500 nM. Averages are shown as black dots and standard deviations are shown as bars. Points have
been distributed on the horizontal axis for clarity.
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applied procedure. As for the binding energy, Figure 5, there
was no simple relationship between the solvation energy and
the observed log EC50. It is only in the complete four-
descriptor model optimized by the neural network that the
relative importance of these two competing energy terms
becomes apparent. Figure S8 shows that there are two major
groups in terms of the solvation energy, reﬂecting well the
categorization into hydrophobic and hydrophilic compounds.
SD of the compound was also found to be an important
descriptor of EC50. This property is deﬁned as the sum of all
bonds between nonhydrogen atoms. Thus, a high value
represents a weakly saturated, compact molecule. It is highly
correlated with the shape attribute (0.99) and molecular
weight (0.95). This measure of the complexity of the ligand
adds important predictive value to the model (Figure 5), as
modulators with high EC50 values in group F (EC50 > 500 nM)
have relatively low complexity.
In summary, the four descriptors have meaningful
interpretations that probably relate to the real, still not fully
understood C99 processing mechanism of γ-secretase. It is also
notable that the model produced, eq 1, has the form of a
nonspeciﬁc general contribution to a high log EC50 for any
compound but subsequently reduced by the four terms
separately, considering the sign conventions of the last two
energy terms discussed above. In other words, any rational
prediction would start with log EC50 ∼6.4 and then work
downward by optimizing the protein−modulator interactions,
the shape, and reducing the dehydration penalty. The most
successful modulators only reach the nanomolar range by such
a combination of strategies.
We further analyzed the chemical property distribution of
the modulators based on their division into NSAIDs and non-
NSAIDs; the results are shown in Figure 6. The non-NSAID
modulators in the data set were generally more eﬃcient, with
lower EC50 values. The modulators with EC50 values <50 nM
were all non-NSAID modulators. For NH and SD, these results
are in accordance with the overall analysis shown in Figure 6.
Notably, as shown in Figure 6, Esol values for the non-NSAID
modulators were signiﬁcantly higher than those for the NSAID
modulators. The NSAID modulators with very high EC50
values bind more weakly to γ-secretase than the other
investigated modulators (Figure 6). In a recent study, γ-
secretase modulators were found to have a synergistic eﬀect
toward their modulatory activity for non-NSAID and NSAID
combinations, indicating that these two types of γ-secretase
modulators may target diﬀerent binding sites in the protein.50
Implications for the Molecular Mechanism of Familial
AD. Previous studies suggest that γ-secretase should bind to its
natural substrate C99 long enough to let the substrate be
cleaved repeatedly.51 The reaction kinetics are aﬀected by both
enzyme and substrate as seen from mutation studies.52 The
non-NSAID γ-secretase modulators induce conformational
changes of γ-secretase that aﬀect the production of Aβ42
peptides.53 These ﬁndings are consistent with full-atom MD
Figure 6. Distribution of values of log EC50 and of the best descriptors of log EC50 divided into groups as in Figure 5. Averages are shown as black
dots and standard deviations shown as bars. Points have been distributed on the horizontal axis for clarity.
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simulations showing that the binding aﬃnity between the
semiopen state of γ-secretase and C99 increases the retention
time and thereby the extent of trimming within the protein
complex, while the open state binds C99 less well and
accordingly releases it after a relatively short time (the FIST
model).40 Thus, we have a complete mechanistic working
model of γ-secretase that explains both the eﬀect of modulators
and the impact of PSEN1 mutations that cause early-onset AD,
either favoring or disfavoring the compact stability of the
protein complex to favor the open conformation state that is
less catalytically proﬁcient and releases Aβ earlier at longer
lengths.54,55 We refer to this as the FIST (Fit, Stay, Trim)
mechanism where the trimming of C99 is controlled by its
adequate “squeezing”.
■ CONCLUSIONS
There is urgent need to understand the molecular basis for
modulation of γ-secretase to develop new therapies that
modulate the activity of this enzyme complex. Many γ-
secretase modulators reduce Aβ42 production and increase
Aβ38 peptides,
31,36 but there is no molecular mechanism that
can explain their function. One of the most haunting questions
is why so many diverse molecules, including molecules such as
ibuprofen, selectively lower the Aβ42 production.
We explored the activity of 60 of the most known
modulators with the help of structural and chemical
descriptors. Our compiled data set (GSL60) contains
structurally and chemically diverse γ-secretase modulators
with a wide range of EC50 values. Using neural network
optimization, we have identiﬁed a chemically meaningful
model based on only four descriptors, which explains most of
the variation in the observed log EC50. The four descriptors are
the number of hydrogen acceptor sites, the complexity of the
drug measured by SD, the desolvation energy penalty measured
by the solvation energy of the drug, and the binding free
energy to the protein. The model reveals the major importance
of strong, nonspeciﬁc binding to multiple modulatory sites,
mainly by favoring large complex molecules with a small
dehydration penalty, many hydrogen-bond acceptor sites, and
a favorable free energy of binding to the protein. We envision
that our model can be used for virtual screening of new γ-
secretase modulator candidates.
Our FIST (Fit, Stay, Trim) mechanism of γ-secretase
rationalizes the outcome of both modulators and pathogenic
PSEN1 mutations working to opposite eﬀects: modulators
favor tight substrate association and increase the retention time
of C99, whereas pathogenic PSEN1 mutations favor the open
state of the protein and shorten the retention time of C99 to
increase the average length of the produced Aβ peptides.
Accordingly, our model suggests that many molecules can
modulate cleavage simply by contributing their binding energy
to stabilize the compact ternary complex with C99.
Our mechanism requires further experimental support. It
only captures some properties that correlate with experimental
EC50 for 60 drugs, without actually knowing the modulatory
sites themselves. Also, the diversity of the data set reduces the
explanatory power for low-aﬃnity drugs. This however also
shows that experimental claims based on a few modulators may
be misleading as the modulators and their function via multiple
descriptors are chemically diverse, a fact that justiﬁes our
computational approach, which will be expanded to include
more compounds and more physiologically relevant chemical
models in the future.
■ COMPUTATIONAL METHODS
GSL60 γ-Secretase Modulator Data Set. The γ-secretase
modulators were selected based on the diversity in structure
and EC50 based on two extensive reviews, which covered most
key patents and articles published in this ﬁeld until 2016.35,36
The other compounds were added according to the papers
published by diﬀerent groups in 2016 and 2017.47,56−59 The
ﬁnal curated data set (GSL60) contains 60 compounds from
25 research groups with EC50 values ranging from 6 nM to 250
μM, that is, it spreads well the range of values with
representatives of all major compound classes. Out of 60
modulators, 13 are NSAIDs, 46 are non-NSAIDs, and 1
(compound 53) is a natural product included as a control as
these are too diverse for modeling with limited data available.
Some examples include the NSAIDs ibuprofen (compound 26
in the data base) and Tarenﬂurbil (Flurizan, compound 19)
and three aminothiazoles (compounds 57−59), which have
shown promising activity in the nanomolar range recently.60
Compounds were selected broadly from major companies such
as pyridopyrazine-1,6-diones and amides from Pﬁzer, triazole
derivatives from Merck, carboxylic acids and anilines from
GSK and Janssen, thienopyrimidines from Boehringer-
Ingelheim (B-I), and several anilines and tricyclic amines
from Bristol-Meyers Squibb. Because most of the develop-
ments in γ-secretase modulators are relatively recent, most of
the compounds were published after 2011. A summary of the
data set is given in the Supporting Information, Table S1.
To build the molecules of the data set for further processing,
the 3D coordinates for each compound were individually
searched and downloaded from the PubChem database.61
Structures that could not be found in PubChem were
generated by the MarvinSketch tool. Then, all structures
were optimized at pH 7.0 using the LigPrep tool of the
Schrödinger Suite with the OPLS3 force ﬁeld, which was
speciﬁcally developed for good accuracy when applied to drug-
like molecules.62 The molecular structures were subsequently
used for calculation of the QSAR descriptor values.
Calculation of Quantum Mechanical Descriptors. All
quantum mechanical calculations presented in this study were
performed using DFT with the Turbomole 7.0 software. To
speed up calculation, we used the resolution of identity
approximation for geometry optimization of all 60 molecules,
which does not aﬀect the obtained equilibrium structure but
accelerates convergence.63 We used the B3LYP functional and
the 6-31G(d,p) basis set for geometry optimization. Solvent
eﬀects were included using the COSMO model.64 Speciﬁcally,
we hypothesized that the diﬀerence between the COSMO
solvation energy of a water- and a protein-like environment
might provide an estimate of the nonspeciﬁc binding of the
modulators to the protein. Thus, dielectric constants of 4 and
80 were both used for computing Esol. In addition, Koopmans’
theorem was applied to the DFT Kohn−Sham orbital
energies65 to compute quantum mechanical descriptors such
as the electronegativity, chemical potential, ionization
potential, electron aﬃnity, chemical hardness and softness,
and electrophilicity index.
Calculation of the Binding Free Energy. The free
energy of binding the modulators to γ-secretase (ΔGbind) was
calculated using AutoDock Vina.66 The structure used for
docking was previously established by multitemplate homology
modeling and relaxed by MD simulations for 500 ns.40
Multiseed MD simulations revealed three distinct conforma-
ACS Omega Article
DOI: 10.1021/acsomega.8b02196
ACS Omega 2018, 3, 18078−18088
18085
tional states of γ-secretase that diﬀer in the access to the
cleavage site ﬂanked by helices 2, 3, and 6.40 We identiﬁed the
semiopen state as having optimal contacts and the longest
residence time for C99, and thus, we suggested that this is the
normal innocent form of the protein complex that produces
the shortest Aβ isomers.40 In contrast, mutations in PSEN1
commonly reduce hydrophobic packing and protein stability in
a way that favors the open conformation state and correlates
directly with the clinical severity of the mutations. The open
state has shorter residence time of C99 because of nonoptimal
substrate−protein interactions and thus releases Aβ peptides
with longer lengths, according to our model, which is referred
to as the FIST (Fit, Stay, Trim) mechanism below.54,55 As this
open state is probably characteristic of PSEN1 mutants, we
used the semiopen state here as it represents the dominating
state of the wild-type protein.
The full protein complex structure of the semiopen state was
ﬁrst repaired by FoldX67 through RepairPDB function to
remove crashes and then processed by MGL tools and
converted to PDBQT format. DFT-optimized structures of the
modulators were used and converted to PDBQT format using
the Open Babel software with the default setup.68 A grid box
size of 70 × 60 × 80 Å was used with the whole
transmembrane region as the target for docking. The top
scores for all investigated modulators were used as estimates of
the binding energy to γ-secretase.
Topological and MMGBSA Energy Descriptors. All
topological descriptors were calculated based on the DFT-
optimized structures, by using the Chem3D 16.0 software. The
MMGBSA descriptors were calculated using Prime of the
Schrödinger Suite and the OPLS3 force ﬁeld62 applied to the
semiopen structure. The initial coordinates of the protein
modulator complexes were obtained from Glide docking using
standard precision and used as input during the MMGBSA
calculations.69,70
QSAR Models. After collecting all descriptors, the data set
was normalized and divided into a training data set (60%) and
test data set (40%). To avoid bias, 10-fold repeated cross-
validation and Y randomization for the best model were
applied during the analysis. The following 10 methods were
used to ensure adequate optimization of the QSAR models:
multiple linear regression (lm), partial least-squares regression
(pls), generalized linear model with stepwise feature selection
(glmStepAIC), elastic net regression (glmnet), lasso regression
(lassoRMSE), random forest (rf), random forest recursive
feature elimination (rfRFE), support vector machine using
radial function (svmRadial), support vector machine recursive
feature elimination (svmRFE), and neural networks (nnet).
These methods were applied using a wrapper package called
RRegrs in R,42 using the standard parameters. For the time-
consuming methods svmRFE and rfRFE, 3- and 5-fold cross-
validation with one repeat was applied, respectively. The
selection of the models was based on the obtained R2 and
RMSE.
Finally, the models were subject to explicit external
validation using a distinct secondary data set of 10 modulators.
These 10 modulators diﬀer from the 60 molecules of the
GSL60 data set and were randomly selected among alternative
modulators with similar log EC50 range. Details on these 10
additional modulators used for external validation are provided
in Supporting Information, Table S2.
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Ideas and Concepts to Tackle γ-Secretases in Alzheimer’s Disease and
Beyond. Annu. Rev. Pharmacol. Toxicol. 2015, 55, 419−437.
(30) Weggen, S.; Eriksen, J. L.; Sagi, S. A.; Pietrzik, C. U.; Golde, T.
E.; Koo, E. H. Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs
Preserve Intramembrane Cleavage of the Amyloid Precursor Protein
(APP) and ErbB-4 Receptor and Signaling through the APP
Intracellular Domain. J. Biol. Chem. 2003, 278, 30748−30754.
(31) Weggen, S.; Eriksen, J. L.; Das, P.; Sagi, S. A.; Wang, R.;
Pietrzik, C. U.; Findlay, K. A.; Smith, T. E.; Murphy, M. P.; Bulter, T.;
et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently
of cyclooxygenase activity. Nature 2001, 414, 212−216.
(32) Ohki, Y.; Higo, T.; Uemura, K.; Shimada, N.; Osawa, S.;
Berezovska, O.; Yokoshima, S.; Fukuyama, T.; Tomita, T.; Iwatsubo,
T. Phenylpiperidine-type γ-secretase modulators target the trans-
membrane domain 1 of presenilin 1. EMBO J. 2011, 30, 4815−4824.
(33) Sagi, S. A.; Lessard, C. B.; Winden, K. D.; Maruyama, H.; Koo,
J. C.; Weggen, S.; Kukar, T. L.; Golde, T. E.; Koo, E. H. Substrate
Sequence Influences γ-Secretase Modulator Activity, Role of the
Transmembrane Domain of the Amyloid Precursor Protein. J. Biol.
Chem. 2011, 286, 39794−39803.
(34) Wolf, M. γ-Secretase as a Target for Alzheimers Disease. Curr.
Top. Med. Chem. 2002, 2, 371−383.
(35) Oehlrich, D.; Berthelot, D. J.-C.; Gijsen, H. J. M. γ-Secretase
modulators as potential disease modifying anti-Alzheimer’ s drugs. J.
Med. Chem. 2010, 54, 669−698.
(36) Bursavich, M. G.; Harrison, B. A.; Blain, J.-F. Gamma Secretase
Modulators: New Alzheimer’s Drugs on the Horizon? J. Med. Chem.
2016, 59, 7389−7409.
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